SUPPLEMENTARY INFORMATION



Supplementary Figure 1. Effect of pridopidine treatment on wild-type. (A) Pridopidinetreated WT mice displayed improved motor learning at 2 months of age compared with vehicle-treated WT mice. (B,C) Pridopidine treatment did not improve motor function in WT mice in the accelerating rotarod test (B), climbing test (C, D) or the spontaneous activity test (E). (F-G) The performance of pridopidine-treated WT mice was similar to that of vehicletreated WT mice in the open field (F), elevated plus maze (G) and forced swim (H) tests of anxiety- and depressive-like phenotypes.

(A-H) Box-and-whiskers plots show median (line within box), 25th and 75th percentile (bounds of box), and minimum and maximum values (bars);

(**A-G**) n = 15-21 WT-vehicle, n = 11-19 WT-pridopidine (30 mg/kg); *p < 0.05, **p < 0.01, ***p < 0.001 by two-tailed student's t-test.

(H) n = 4 WT-vehicle and WT-pridopidine (30 mg/kg); *not significant* by two-tailed student's t-test.



Supplementary Figure 2. Effect of late pridopidine treatment on manifest YAC128 HD mice. (A) Vehicle-treated YAC128 HD mice displayed motor learning deficits in the rotarod training task at 10 months of age. Such deficits were not improved with late pridopidine treatment. (B) Vehicle-treated YAC128 HD mice exhibited motor deficits in the accelerating rotarod, which late pridopidine treatment could not improve. (C, D) Anxiety-like phenotypes were also evaluated in vehicle-treated YAC128 HD mice at 9.5 months of age; however, no differences in time spent in the centre in the OF (C) as well as time spent in the open arms in the EPM (D) were observed between genotypes. Also, no effect of pridopidine was observed in either test in treated YAC128 HD mice. (E) When depressive-like phenotypes were evaluated, vehicle-treated YAC128 HD mice spent more time immobile compared to vehicle-treated WT mice. Pridopidine treatment improved depressive-like phenotypes by reducing the time spent immobile in treated YAC128 HD mice.

(A-E) Box-and-whiskers plots show median (line within box), 25th and 75th percentile (bounds of box), and minimum and maximum values (bars); n = 7-12 WT-vehicle, n = 8 YAC128-vehicle, n = 7-10 YAC128-pridopidine; *p < 0.05, **p < 0.01, ***p < 0.001 by one-way ANOVA with Fisher's LSD post hoc analysis.



Supplementary Figure 3. Effect of early pridopidine treatment on striatal and CC volume in YAC128 HD mice at 7 and 10 months of age by MRI. (A) Vehicle-treated YAC128 HD mice displayed decreased striatal volumes at 7 and 10 months of age by structural MRI, which were not rescued by pridopidine treatment (10 and 30 mg/kg). (B) In addition, decreased CC volume was observed in vehicle-treated YAC28 HD mice at 7 and 10 months of age. Pridopidine treatment had no effect on CC volume in treated YAC128 HD mice.

(**A**,**B**) Box-and-whiskers plots show median (line within box), 25th and 75th percentile (bounds of box), and minimum and maximum values (bars); n = 8 WT-vehicle, n = 8 YAC128-vehicle, n = 8 YAC128-pridopidine (10 mg/kg), n = 8 YAC128-pridopidine (30 mg/kg); ***p < 0.001 by one-way ANOVA with Fisher's LSD post hoc analysis.

CC = corpus callosum; Pri = Pridopidine; Veh = Vehicle; Low = 10 mg/kg; High = 30 mg/kg.



Supplementary Figure 4. RNA-seq analysis of differentially expressed genes. Venn analysis of striatal genes upregulated in vehicle-treated YAC128 HD mice compared with vehicle-treated WT mice, and striatal genes downregulated in the striatum of pridopidine-treated YAC128 HD mice.



Supplementary Figure 5. Analysis of pridopidine concentration in plasma of early treated YAC128 HD mice. In the early pridopidine treatment cohort, mean pridopidine concentration in plasma was lower in YAC128 HD mice treated with the low dose of pridopidine than in YAC128 HD mice treated with the high dose of pridopidine.

Box-and-whiskers plots show median (line within box), 25th and 75th percentile (bounds of box), and minimum and maximum values (bars); n = 14 YAC128-pridopidine (10 mg/kg), n = 15 YAC128-pridopidine (30 mg/kg); ***p < 0.001 by one-way ANOVA with Fisher's LSD post hoc analysis.

Pri = Pridopidine; Low = 10 mg/kg; High = 30 mg/kg.

									S	ample	e size								
		2	montl	hs	4	month	าร	6	montl	าร	8	mont	hs	10	mon	ths	12	mon	ths
Genotype	Treatment	F	Μ	Ν	F	М	Ν	F	Μ	Ν	F	М	Ν	F	Μ	Ν	F	Μ	Ν
WT	Vehicle	11	10	21	11	9	20	10	8	18	9	8	17	8	8	16	7	7	14
YAC128	Vehicle	9	10	19	9	10	19	9	10	19	9	9	18	9	9	18	9	9	18
YAC128	Pri (10 mg/kg)	10	10	20	10	10	20	10	10	20	10	10	20	10	10	20	10	9	19
YAC128	Pri (30 mg/kg)	10	9	19	10	9	19	10	9	19	10	9	19	10	8	18	10	8	18

Supplementary	v Table 1. Earl	v pridopidine	treatment of	cohort same	ole size.
e appiententary		, biiachianie			

Supplementary Table 2. Percentage of survival in all groups in early pridopidine treatment cohort.

Genotype	Treatment	Initial N	Final N	Survival (%)
WT	Vehicle	21	14	66.66
YAC128	Vehicle	19	18	94.73
YAC128	Pri (10 mg/kg)	20	19	95
YAC128	Pri (30 mg/kg)	19	18	94.73

Supplementary Table 3. Late pridopidine treatment cohort sample size for each behavioural test.

OF = open field; EPM = elevated plus maze; Acc. RR = accelerating rotarod; FST = forced swim test

		Init	ial saı size	mple	OI	san ⁼ san	nple	EP	M sar size	nple	sa	Acc. R mple	R size	FS	T sar size	nple
		8	mont	:hs	9.5	5 mor	nths	9.	5 mor	nths	1	0 mon	ths	10) mon	iths
Genotype	Treatment	F	Μ	Ν	F	М	Ν	F	Μ	Ν	F	М	Ν	F	Μ	Ν
WT	Vehicle	3	9	12	3	9	12	3	7	10	3	7	10	3	9	12
YAC128	Vehicle	3	5	8	3	5	8	3	5	8	3	5	9	3	5	8
YAC128	Pridopidine	3	7	10	3	7	10	2	5	7	3	7	10	3	7	10

Supplementary Table 4. Accelerating rotarod sample size at each analysis point for early pridopidine treatment cohort.

							Ac	celera	ating I	rotarc	od tes	t sam	ple si	ze					
		2	mont	hs	4	montl	hs	6	mont	hs	8	mont	hs	10	mont	ths	12	mon	ths
Genotype	Treatment	F	Μ	Ν	F	Μ	F	F	Μ	Ν	F	М	Ν	F	Μ	Ν	F	Μ	Ν
WT	Vehicle	11	10	21	10	8	18	9	8	17	10	7	17	8	6	14	7	4	11
YAC128	Vehicle	9	9	18	9	8	17	8	8	16	8	8	16	6	8	14	6	8	14
YAC128	Pri (10 mg/kg)	10	10	20	10	10	20	10	10	20	10	10	20	10	10	20	10	8	18
YAC128	Pri (30 mg/kg)	10	6	16	10	9	19	10	9	19	10	9	19	10	8	18	10	7	17

						0	Climbi	ng te	st sar	nple	size (laten	cy to o	climb)				
		2	mont	hs	4	mont	hs	6	mont	hs	8	mont	hs	10	mont	ths	12	mon	ths
Genotype	Treatment	F	Μ	Ν	F	М	F	F	Μ	Ν	F	М	Ν	F	Μ	Ν	F	Μ	Ν
WT	Vehicle	11	8	19	10	8	18	8	9	17	8	9	16	7	7	14	7	4	11
YAC128	Vehicle	9	9	18	9	8	17	8	8	16	8	8	16	6	8	14	8	8	16
YAC128	Pri (10 mg/kg)	10	10	20	10	10	20	10	10	20	10	10	20	10	10	20	10	9	19
YAC128	Pri (30 mg/kg)	10	9	19	10	9	19	10	9	19	10	9	19	10	8	18	10	7	17

Supplementary Table 5. Climbing test (latency to climb) sample size at each analysis point for early pridopidine treatment cohort.

							Clim	oing t	est sa	ample	e size	(clim	bing t	ime)					
		2	mont	hs	4	montl	hs	6	mont	hs	8	montl	าร	10	mont	ths	12	mon	ths
Genotype	Treatment	F	Μ	Ν	F	Μ	F	F	Μ	Ν	F	Μ	Ν	F	Μ	Ν	F	Μ	Ν
WT	Vehicle	10	8	19	9	8	17	8	9	17	8	9	16	7	7	14	7	4	11
YAC128	Vehicle	9	9	18	9	9	18	8	8	16	8	8	16	6	8	14	8	8	16
YAC128	Pri (10 mg/kg)	10	10	20	10	10	20	10	10	20	10	10	20	10	10	20	10	9	19
YAC128	Pri (30 mg/kg)	10	9	19	10	9	19	10	9	19	10	9	19	10	8	18	10	7	17

Supplementary Table 6. Climbing test (climbing time) sample size at each analysis point for early pridopidine treatment cohort.

Supplementary Table 7. Spontaneous activity sample size in early pridopidine treatment cohort.

		Spontaneo	us activity s	sample size
			12 months	
Genotype	Treatment	F	М	N
WT	Vehicle	5	5	10
YAC128	Vehicle	8	7	15
YAC128	Pri (10 mg/kg)	10	7	17
YAC128	Pri (30 mg/kg)	11	9	20

Supplementary Table 8. Psychiatric-like behaviour test sample sizes in early pridopidine treatment cohort.

		OF sa	ample	e size	EPM	sample	e size	FST	sample	e size
		6	montl	hs	8	month	S	1	2 montl	าร
Genotype	Treatment	F	ш	М	F	М	Ν	F	Μ	Ν
WT	Vehicle	9	8	17	9	7	16	0	4	4
YAC128	Vehicle	7	9	16	7	7	14	0	8	8
YAC128	Pri (10 mg/kg)	10	9	19	10	10	20	0	9	9
YAC128	Pri (30 mg/kg)	10	7	17	8	8	16	0	8	8

Enrichment category	Term	P-value	Adjusted P-value	Genes
Jensen COMPARTMENTS	Bcl-2_family_protein_complex	2.22466E-05	0.003001716	EGR1;EGR2;DUSP1;TIPARP;PLK2;LMO2;IRS2;FOS;DUSP6; GADD45G;NR4A1;BCL6;ALDH1A1
Jensen COMPARTMENTS	NF-kappaB_complex	1.92116E-05	0.003001716	EGR1;NR4A1;BCL6;DUSP1;PELI1;CREM;FOSB;FOS;JUNB;F OSL2;GADD45G
Jensen COMPARTMENTS	IgM_B_cell_receptor_complex	2.87934E-05	0.003001716	EGR1;NR4A1;DUSP5;PER1;BCL6
Jensen COMPARTMENTS	NELF_complex	8.46348E-06	0.003001716	EGR1;ARC;DUSP1;FOS;DUSP6
Jensen COMPARTMENTS	lgM_immunoglobulin_complex	0.00043676	0.036425777	EGR1;NR4A1;DUSP5;PER1
Jensen COMPARTMENTS	BCL-2_complex	0.000637208	0.037959417	EGR1;NR4A1;BCL6;DUSP1;TIPARP;LMO2;ALDH1A1;IRS2;F OS;GADD45G
Jensen COMPARTMENTS	Calcitonin_family_receptor_complex	0.000573657	0.037959417	DUSP5;CREM;FOS
Jensen COMPARTMENTS	Neuron_projection	0.000947523	0.04390188	RGS2;ARC;TENM2;PLK2;AKAP9;DNER;KCNA4;HTR1B;FOS
Jensen COMPARTMENTS	calciumand_calmodulin- dependent_protein_kinase_complex	0.000934817	0.04390188	EGR1;ARC;FZD5;FOS
Jensen COMPARTMENTS	Dendrite	0.001549023	0.053828564	ARC;TENM2;PLK2;AKAP9;DNER;HTR1B
Jensen COMPARTMENTS	GO:0005667	0.001363622	0.053828564	NR4A3;LMO2;CREM;FOS;JUNB
Jensen COMPARTMENTS	C-fiber	0.001422541	0.053828564	EGR1;HTR1B;FOSB;FOS
Jensen COMPARTMENTS	Female_germ_cell_nucleus	0.001992273	0.05934127	EGR4;DUSP1;GPR3;MEST;DUSP6
Jensen COMPARTMENTS	Germinal_vesicle	0.001992273	0.05934127	EGR4;DUSP1;GPR3;MEST;DUSP6
Jensen COMPARTMENTS	interleukin-9_receptor_complex	0.002139002	0.059464246	EGR1;IRS2
Jensen COMPARTMENTS	Aryl_hydrocarbon_receptor_complex	0.003559934	0.092780788	TIPARP;LMO2;ALDH1A1;GADD45G
Jensen COMPARTMENTS	Activin_AB_complex	0.005861412	0.14377698	EGR4;DUSP6;GADD45G

Supplementary Table 9. Functional enrichment for DEGs common to the 10 mg/kg and 30 mg/kg pridopidine YAC128 HD groups.

AKAP9;KCNA4	0.227193986	0.019512531	voltage- gated_potassium_channel_complex	Jensen COMPARTMENTS
FNDC5;FOS	0.227193986	0.021428904	Glutamate_decarboxylase_complex	Jensen COMPARTMENTS
PDP1;EGR2	0.227193986	0.019984485	Microneme	Jensen COMPARTMENTS
DUSP1;LMO2	0.227193986	0.017673088	DSIF_complex	Jensen COMPARTMENTS
DUSP5;EGR1	0.227193986	0.021428904	Heparanase_complex	Jensen COMPARTMENTS
EGR2;HTR1B	0.227193986	0.020461217	Calyx_of_Held	Jensen COMPARTMENTS
TENM2;RGS2;ARC;PLK2;DNER;AKAP9;KCNA4;HTR1B;FOS;I QGAP2	0.227193986	0.021483301	Cell_projection	Jensen COMPARTMENTS
DUSP5;EGR1	0.193019267	0.013423402	lgD_B_cell_receptor_complex	Jensen COMPARTMENTS
DUSP5;EGR1	0.193019267	0.013423402	lgD_immunoglobulin_complex	Jensen COMPARTMENTS
AKAP9;CREM	0.183297034	0.011868153	cyclic- nucleotide_phosphodiesterase_complex	Jensen COMPARTMENTS
EGR1;NR4A1;BCL6;DUSP1;ALDH1A1;FOS	0.181521044	0.011317859	BAX_complex	Jensen COMPARTMENTS
RND3;JUNB	0.179439769	0.01075778	interleukin-6_receptor_complex	Jensen COMPARTMENTS
CREM;FOS	0.174526625	0.010044698	CGRP_receptor_complex	Jensen COMPARTMENTS
RGS2;FOSB	0.174526625	0.009696402	SMAD2_protein_complex	Jensen COMPARTMENTS
FNDC5;EGR4;IRS2	0.174526625	0.009725295	HIR_complex	Jensen COMPARTMENTS
ARC;TENM2;PLK2;AKAP9;DNER;HTR1B	0.162012006	0.008158878	Somatodendritic_compartment	Jensen COMPARTMENTS
RGS2;ARC;TENM2;PLK2;AKAP9;DNER;KCNA4;HTR1B;FOS	0.162012006	0.008004064	Neuron_part	Jensen COMPARTMENTS
FAM184B;LMO2;ALDH1A1;GPR3	0.156870596	0.007147581	gamma-secretase_complex	Jensen COMPARTMENTS
EGR1;NR4A1;BCL6;DUSP1;IRS2;FOS	0.145085932	0.006262702	Fatty_acid_synthase_complex	Jensen COMPARTMENTS

Jensen	Potassium_channel_complex	0.019984485	0.227193986	AKAP9;KCNA4
COMPARIMENTS				
Jensen COMPARTMENTS	serotonin-activated_cation- selective_channel_complex	0.019512531	0.227193986	HTR1B;FOS
Jensen COMPARTMENTS	Ciliary_necklace	0.021793188	0.227193986	FOS
Jensen COMPARTMENTS	Postsynaptic_actin_cytoskeleton	0.019094754	0.227193986	POU3F4
Jensen COMPARTMENTS	Filopodium	0.025485098	0.259202093	TENM2;IQGAP2
Jensen COMPARTMENTS	Myb_complex	0.02695452	0.264919806	EGR1;LM02;FOS;RREB1
Jensen COMPARTMENTS	Set3_complex	0.028642582	0.264919806	ALDH1A1;FOS;DUSP14
Jensen COMPARTMENTS	Pituitary_gonadotropin_complex	0.030494366	0.264919806	EGR1;CREM;DUSP6
Jensen COMPARTMENTS	Survivin_complex	0.030177355	0.264919806	EGR1;NR4A1;ALDH1A1;RND3
Jensen COMPARTMENTS	NMS_complex	0.028166347	0.264919806	TENM2;HTR1B
Jensen COMPARTMENTS	TRAMP_complex	0.028946894	0.264919806	EGR1;EGR4;TIPARP
Jensen COMPARTMENTS	ATP- sensitive_potassium_channel_complex	0.030389479	0.264919806	FNDC5;PDP1
Jensen COMPARTMENTS	pre-B_cell_receptor_complex	0.031526496	0.268296917	EGR2;BCL6
Jensen COMPARTMENTS	MIS_complex	0.032680198	0.271975904	NR4A3;CREM
Jensen COMPARTMENTS	Dendritic_spine	0.03326324	0.271975904	ARC;TENM2
Jensen COMPARTMENTS	Neuron_spine	0.034441575	0.276194937	ARC;TENM2
Jensen COMPARTMENTS	Pairing_center	0.035176413	0.276765362	PLK2
Jensen COMPARTMENTS	platelet-derived_growth_factor_complex	0.037462778	0.289295897	EGR1;FOSB;FOS
Jensen COMPARTMENTS	Synaptic_membrane	0.038165679	0.289365242	ARC;TENM2;AKAP9

GO Cellular Component miu (Gu	GO Cellular Component dei	GO Cellular Component vol	GO Cellular Component poi	GO Cellular Component filo	GO Cellular Component tra	Jensen Ad COMPARTMENTS	Jensen mF COMPARTMENTS	Jensen Mit COMPARTMENTS cc	Jensen COMPARTMENTS
crotubule organizing center part O:0044450)	ndrite (GO:0030425)	ltage-gated potassium channel complex O:0008076)	tassium channel complex (GO:0034705)	podium (GO:0030175)	nscription factor complex (GO:0005667)	renomedullin_receptor_complex	RNA_editing_complex	tochondrial_permeability_transition_pore omplex	hanceosome
0.033850374	0.027146969	0.015912445	0.016345114	0.007724074	0.006293839	0.04575341	0.046413166	0.043274876	0.041205827
0.400562763	0.385486965	0.290125779	0.290125779	0.274204614	0.274204614	0.328038821	0.328038821	0.316589886	0.306836248
PLK2;AKAP9	TENM2;PLK2;DNER	AKAP9;KCNA4	AKAP9;KCNA4	TENM2;IQGAP2	NR4A1;LMO2;CREM;FOS	DUSP5	NR4A3;CREM	FOSB;HTR1B;FOS	GADD45G;FOSL2

Supplementary Table 10. Functional enrichment for DEGs specific to 30 mg/kg pridopidine YAC128 HD group.

A8;TRPC5;CAMK2D;GRIN3A;HOMER2;PDE1A;STRN;RGS8;TAC1;CYGB
5A3;EGR3;ARPP21;HBEGF
5A3;CAMK2D;TENM3;TGFA;KCNA5;SLC05A1;SNTG2;GNG4;FLRT3;VWC P5K1A;KCNMB4;DRD1;RGS8;GRASP;TRPC5;CXADR;TRPC3;CAV2;HOM PDE4D;TPM1;IQSEC3;HTR1A;KCNJ16;SLC4A8;GRIN3A;NLRP10;VAMP1; '2;STRN;MDGA1;GPR19;HBEGF
35;CAMK2D;HOMER2;CTTNBP2;PDE1A;HTR1A;ELFN1;CYGB;SLC4A8;GR STRN;RGS8;TAC1
)R;CAV2;HOMER2;PDE4D;IQSEC3;TPM1;TGFA;KCNJ16;KCNA5;GRIN3A; 3;PIP5K1A;SPRY2;STRN;DRD1;GRASP
>5;CAMK2D;CXADR;HOMER2;CTTNBP2;DNAH6;TPM1;FLRT3;MAK;TBC1 \RMC4;VAMP1;PIP5K1A;SPRY2;STRN;DRD1
35;CAMK2D;GRIN3A;PDE4D;VWC2L;KCNMB4;KCNJ16;KCNA5
;5;CAMK2D;GRIN3A;PDE4D;VWC2L;KCNMB4;KCNJ16;KCNA5
;;ARPP21;VAMP1;GFRA1;TAC1
CIB2;GNB5
A;DRD1;TAC1;SCRT1
;\VAMP7;CXADR;SYT12;CTTNBP2;CAV2;\VAMP1;TMEM163;CKAP4;SYT6
10;GNG4;CAV2;PIK3R3;GFRA1;RGS8;SYT6
K2D;CXADR;GRIN3A;VAMP7;SYT12;DOK7;IQSEC3;VWC2L;CIB2;VAMP1;
K2D;CXADR;DOK7;CIB2
<pre>{2D;GRIN3A;CXADR;RHEB;HOMER2;PDE1A;STRN;TAC1;CYGB</pre>
<pre><2D;TRPC5;GRIN3A;PDE4D;VWC2L;KCNMB4;KCNJ16;KCNA5</pre>
K2D;TRPC5;PDE4D;KCNMB4;KCNJ16;KCNA5
K2D;GRIN3A;HOMER2;RHEB;PDE1A;STRN;TAC1;CYGB
\$ \$\$`\$\$`\$

L;SPARCL1;TAC1;MDGA1;HIST1H2BC;HBEGF;FGF10 SV2C;CTTNBP2;SYT6 TPM1;MYH11 GRIN3A;HOMER2;IQSEC3;STRN;GRASP	0.321405714 0.321405714 0.359429669	0.034828535 0.035877847 0.041794148	(GO:0005615) synaptic vesicle (GO:0008021) contractile fiber (GO:0043292) synaptic membrane (GO:0097060)	GO Cellular Component GO Cellular Component GO Cellular Component
KCNJ16;KCNMB4;KCNA5 GRIN3A;HOMER2;IQSEC3;STRN;GRASP TLE2;CXADR;USPL1;SEMA3C;RALGAPA2;TGFA;LAMB1;SFRP1;F	0.228621017 0.235780597 0.235780597	0.020490445 0.023505428 0.024126387	voltage-gated potassium channel complex (GO:0008076) postsynaptic membrane (GO:0045211) extracellular space	GO Cellular Component GO Cellular Component GO Cellular Component
KCNMB4;KCNJ16;KCNA5	0.228621017	0.021267071	(GO:0001917) potassium channel complex (GO:0034705)	GO Cellular Component
NLRP10;CAV2;GFRA1;SYT6 MAK;CIB2	0.196387739 0.228621017	0.015528333 0.019531156	extrinsic component of membrane (GO:0019898) photoreceptor inner segment	GO Cellular Component GO Cellular Component
CXADR;CLDN23;STRN;FRMD4A	0.169073476	0.012582212	tight junction (GO:0005923)	GO Cellular Component
CXADR;CLDN23;FRMD4A;STRN	0.169073476	0.012582212	occluding junction	GO Cellular Component
TRPC5;CAMK2D;PDE4D	0.169073476	0.011839446	calcium channel complex (GO:0034704)	GO Cellular Component
DGAT2;CAV2;CKAP4	0.169006089	0.010218973	lipid particle (GO:0005811)	GO Cellular Component
CAMK2D;CXADR;KCNA5	0.106989791	0.00579521	cell-cell contact zone (GO:0044291)	GO Cellular Component
VAMP7;HOMER2;DCHS1;FAT4	0.106989791	0.005971523	apical part of cell (GO:0045177)	GO Cellular Component
SV2C;GRIN3A;CTTNBP2;HOMER2;IQSEC3;STRN;TMEM163;GRA	0.106989791	0.005840079	synapse part (GO:0044456)	GO Cellular Component
CAMK2D;CXADR;KCNA5	0.084731534	0.003546901	intercalated disc (GO:0014704)	GO Cellular Component
CAMK2D;TRPC5;GRIN3A;PDE4D;VWC2L;KCNMB4;KCNJ16;KCN/	0.081664281	0.002733791	transmembrane transporter complex (GO:1902495)	GO Cellular Component
CAMK2D;TRPC5;GRIN3A;PDE4D;VWC2L;KCNMB4;KCNJ16;KCNA	0.081664281	0.003038671	transporter complex (GO:1990351)	GO Cellular Component
			(GO:0043025)	